Xeris Biopharma Holdings, Inc.

NasdaqGS:XERS Stock Report

Market Cap: US$520.3m

Xeris Biopharma Holdings Management

Management criteria checks 3/4

Xeris Biopharma Holdings' CEO is John Shannon, appointed in Aug 2024, has a tenure of less than a year. total yearly compensation is $1.85M, comprised of 30.9% salary and 69.1% bonuses, including company stock and options. directly owns 0.38% of the company’s shares, worth $1.97M. The average tenure of the management team and the board of directors is 2 years and 3.2 years respectively.

Key information

John Shannon

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage30.9%
CEO tenureless than a year
CEO ownership0.4%
Management average tenure2yrs
Board average tenure3.2yrs

Recent management updates

Recent updates

Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive

Oct 25

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks

Sep 07
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company

Jun 04
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company

Xeris Biopharma: Checking-In On One Of My 'Top Ideas'

Mar 30

Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results

Mar 09
Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up

Mar 06
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth

Jan 05
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth

Xeris Pharmaceuticals Q2 2022 Earnings Preview

Aug 09

Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal

Aug 01

Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven

May 21

Xeris Continues To Execute And Build Long-Term Value Potential

Feb 22

Xeris Biopharma: Market Is Snubbing The Strongbridge Acquisition

Dec 20

CEO Compensation Analysis

How has John Shannon's remuneration changed compared to Xeris Biopharma Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$63m

Jun 30 2024n/an/a

-US$60m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$2mUS$571k

-US$62m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$71m

Mar 31 2023n/an/a

-US$78m

Dec 31 2022US$2mUS$549k

-US$95m

Sep 30 2022n/an/a

-US$133m

Jun 30 2022n/an/a

-US$137m

Mar 31 2022n/an/a

-US$138m

Dec 31 2021US$2mUS$528k

-US$123m

Sep 30 2021n/an/a

-US$94m

Jun 30 2021n/an/a

-US$84m

Mar 31 2021n/an/a

-US$80m

Dec 31 2020US$1mUS$474k

-US$91m

Sep 30 2020n/an/a

-US$102m

Jun 30 2020n/an/a

-US$119m

Mar 31 2020n/an/a

-US$129m

Dec 31 2019US$1mUS$444k

-US$126m

Sep 30 2019n/an/a

-US$113m

Jun 30 2019n/an/a

-US$95m

Mar 31 2019n/an/a

-US$73m

Dec 31 2018US$918kUS$369k

-US$60m

Sep 30 2018n/an/a

-US$49m

Jun 30 2018n/an/a

-US$42m

Mar 31 2018n/an/a

-US$34m

Dec 31 2017US$508kUS$219k

-US$27m

Compensation vs Market: John's total compensation ($USD1.85M) is about average for companies of similar size in the US market ($USD2.16M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Shannon (62 yo)

less than a year

Tenure

US$1,848,153

Compensation

Mr. John P. Shannon served as the President and Chief Operating Officer at Xeris Pharmaceuticals, Inc. since August 18, 2020 until October 2021 and since joining in February 2017 respectively and served as...

Leadership Team

NamePositionTenureCompensationOwnership
John Shannon
CEO & Directorless than a yearUS$1.85m0.38%
$ 2.0m
Steven Pieper
Chief Financial Officer3.2yrsUS$1.61m0.97%
$ 5.0m
Beth Hecht
Chief Legal Officer & Corporate Secretary3.2yrsUS$1.13m0.22%
$ 1.1m
Paul Edick
Senior Advisorless than a yearUS$2.14m0.78%
$ 4.1m
Kenneth Johnson
Senior VP of Global Development & Medical Affairs3.2yrsUS$720.97k0.071%
$ 371.2k
Allison Wey
Senior Vice President of Investor Relations & Corporate Communications6.4yrsno datano data
Brian Conner
SVP of Quality and Chief Compliance & Risk Officerless than a yearno datano data
Kendal Korte
Senior Vice President of Human Resourcesless than a yearno datano data
Kevin McCulloch
Chief Commercial Officerno datano data1.09%
$ 5.7m

2.0yrs

Average Tenure

61yo

Average Age

Experienced Management: XERS's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Shannon
CEO & Directorless than a yearUS$1.85m0.38%
$ 2.0m
John Brooks
Scientific Advisory Board Memberno datano datano data
Orville Kolterman
Member of Scientific Advisory Boardno datano datano data
Jeffrey Sherman
Independent Director3.2yrsUS$175.75k0.080%
$ 418.1k
John Schmid
Lead Independent Director3.2yrsUS$218.25k0.059%
$ 308.4k
Garheng Kong
Independent Non-Executive Director3.2yrsUS$173.25k0.077%
$ 398.3k
W. Ward
Member of Scientific Advisory Boardno datano datano data
Marla Persky
Independent Chairman3.2yrsUS$183.25k0.043%
$ 222.9k
Morey Haymond
Scientific Advisory Board Memberno datano datano data
John Johnson
Independent Non-Executive Director3.2yrsUS$168.25k0.56%
$ 2.9m
Barbar-Jean Bormann-Kennedy
Independent Director3.2yrsUS$183.25k0.039%
$ 200.7k
Dawn Halkuff
Independent Director3.2yrsUS$175.75k0.042%
$ 219.6k

3.2yrs

Average Tenure

65.5yo

Average Age

Experienced Board: XERS's board of directors are considered experienced (3.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:09
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xeris Biopharma Holdings, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chase KnickerbockerCraig-Hallum Capital Group LLC
Robin Garner KalleyCraig-Hallum Capital Group LLC
Oren LivnatH.C. Wainwright & Co.